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PPharmacogenetic Effect of Factor XIII
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ibrinolytic Therapy for Acute Myocardial Infarction
rancisco Marı´n, MD, PHD,* Rocı´o González-Conejero, PHD,† Kaeng W. Lee, MRCP,‡
avier Corral, PHD,† Vanessa Roldán, MD, PHD,§ Francisca López, MD, Francisco Sogorb, MD,*
uan Caturla, MD, PHD, Gregory Y. H. Lip, MD, FESC, FACC,‡ Vicente Vicente, MD, PHD†
licante and Murcia, Spain; and Birmingham, England
OBJECTIVES The aim of this study was to evaluate the pharmacogenetic role of the factor XIII (FXIII)
valine 34 leucine (Val34Leu) polymorphism in the fibrinolytic therapy of acute myocardial
infarction (MI).
BACKGROUND Fibrinolytic therapy is an established treatment for acute MI, but up to 40% of treated
patients do not achieve optimal tissue reperfusion. The FXIII Val34Leu polymorphism is one
of the most relevant functional polymorphisms described in the haemostatic system. The
common Leu34 allele associates with an increased FXIII-transglutaminase activity, which
results in an increased and faster rate of fibrin stabilization.
METHODS We genotyped this polymorphism in 293 consecutive MI patients (62 12 years; 231 males)
from two different European populations. All patients were treated with standard doses of
fibrinolytic drugs. Noninvasive assessment of the efficacy of coronary fibrinolysis was
evaluated by serial electrocardiograms and creatine kinase time-activity curves. The clinical
outcome was also re-evaluated at 24 h (death, reinfarction, or urgent revascularization).
RESULTS Multivariate analysis showed that Leu34 carriers displayed a significantly less efficient
fibrinolysis than carriers of Val/Val genotype (p  0.021; odds ratio [OR] 1.90, 95%
confidence interval [CI] 1.10 to 3.28). At 24 h, Leu34 allele carriers had the worst outcome
(p  0.006; OR 2.14, 95% CI 1.25 to 3.68). Interestingly, the combination of the Leu34
allele and nonsmoking status increased the risk of non-reperfusion criteria (p  0.003, OR
3.77), and worse outcomes at 24 h (p  0.001, OR 4.55).
CONCLUSIONS In a large cohort of nonselected and consecutive acute MI patients from two different
European populations, we show clinical evidence that the presence of the Leu34 allele reduces
the efficacy of fibrinolytic therapy. (J Am Coll Cardiol 2005;45:25–9) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.051American College of Cardiology Foundation
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tibrinolytic therapy is used to achieve the most important
bjective in patients with an acute myocardial infarction
MI), to open quickly the coronary flow after the occurrence
f an acute coronary occlusion. Indeed, fibrinolytic therapy
eads to better survival, recovery of left ventricular function,
nd remodelling following acute MI (1–3). Unfortunately,
pproximately 40% of treated patients do not achieve
ptimal tissue perfusion (4), and the potential benefits are
imited by early (thrombotic) re-occlusion of the infarct-
elated artery (5). However, few factors have been identified
o be involved in this inter-individual heterogeneity, such as
ge, delay between symptom onset and fibrinolytic therapy,
moking habit, and infarct size or site (6,7).
Coagulation factor XIII (FXIII) is a tetrameric structure
onsisting of two A (active) and two B subunits. Calcium
From the *Cardiology Department, Hospital General Universitario, Alicante,
pain; †Centro de Hemodonación, Universidad de Murcia, Murcia, Spain; ‡Hae-
ostasis, Thrombosis, and Vascular Biology Unit, University Department of Medi-
ine, City Hospital, Birmingham, England; §Hematology Unit, Hospital de San
icente, Alicante, Spain; and the Intensive Care Unit, Hospital General Universi-
ario, Alicante, Spain. This study has been supported by FIS 00/0328 and
AF2003-00840 (MCYT & FEDER). Drs. Corral and González-Conejero are
ontratados de Investigación Ramón y Cajal from the Universidad of Murcia.e
Manuscript received July 29, 2004; revised manuscript received September 9, 2004,
ccepted September 20, 2004.nd thrombin activate factor XIII in the final phase of the
oagulation process. Activated FXIII catalyzes the forma-
ion of covalent gamma-glutamyl-gamma-lysine bonds be-
ween fibrin monomers, increasing the resistance of fibrin to
egradation by plasmin (8). Multiple polymorphisms have
een described in the FXIII-A subunit gene. A common
-to-T polymorphism in exon 2 causes a valine (Val) to
eucine (Leu) change at position 34, three amino acids
pstream to the thrombin cleavage site. This Val34Leu
olymorphism affects the function of FXIII by increasing
he rate of FXIII activation by thrombin, which results in an
ncreased and faster rate of fibrin stabilization (9,10).
owever, the thrombotic role of this polymorphism is
ontroversial and might be specific to populations (11–14).
In a small and retrospective cohort of survivors of
remature MI, our group observed—for the first time—that
eu34 allele carriers could show more “resistance” to fi-
rinolytic therapy (15). In the present report, we prospec-
ively studied an unselected, consecutive cohort of acute MI
atients, eligible for fibrinolytic treatment, from two differ-
nt European populations, and noninvasively assessed the
fficacy of fibrinolytic therapy. Again, our hypothesis was
hat the presence of the Leu34 allele reduces the clinical
fficacy of fibrinolytic therapy for acute MI.
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atients. From September 2002 to March 2004, we in-
luded 293 consecutive acute MI patients (mean age 61.8
2.3 years; 231 males) from two different European popu-
ations: 170 from City Hospital, Birmingham, United
ingdom (this consisted of 109 white Caucasians and 61
ndo-Asians) and 123 from Hospital General Universitario,
licante, Spain (all white Caucasian), who were eligible for
brinolytic therapy. Both are University tertiary hospitals
ith 800 and 915 beds, respectively. Although at the time of
his study there was no formal primary percutaneous coro-
ary intervention (PCI) program for acute MI in both
ospitals, about 88 patients were not included in the present
tudy as primary PCIs were performed. All recruited sub-
ects gave their informed consent to enter the study, which
ad been approved by the local research committee and was
erformed in accordance with the Declaration of Helsinki,
s amended in Edinburgh in 2000.
Major cardiovascular risk factors (current smoking status,
ypercholesterolemia, diabetes and hypertension) were re-
orded. Clinical features of patients and controls are indi-
ated in Table 1. All patients were treated with standard
oses of fibrinolytic drugs (tenecteplase, n 199; streptoki-
ase, n 87; and recombinant tissue plasminogen activator,
 9). Delay in initiation of fibrinolytic drugs from
ymptom onset was recorded.
Abbreviations and Acronyms
CI  confidence interval
CK  creatine kinase
FXIII  factor XIII
Leu  leucine
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous coronary intervention
Val  valine
able 1. Clinical Characteristic and Genetic Frequencies of Myo
All
Patients
293
ge (yrs) 61.8  12.3
ale gender (%) 231 (78.8)
moking habit (%) 144 (49.1)
ypertension (%) 140 (47.8)
iabetes (%) 74 (25.3)
ypercholesterolemia (%) 145 (49.5)
enotype (%)
Val/Val 184 (62.8)
Val/Leu 96 (32.8)
Leu/Leu 13 (4.4)
llele
Val34 0.792
Leu34 0.208
ypertension was defined as blood pressure 140 mm Hg systolic or 90 mm Hg
ubject was under treatment with chronic antihypertensive therapy. Current/form
ypercholesterolemia was defined as a total serum cholesterol level 5.72 mmol/l (220 m
Val  valine; Leu  leucine.ssessment of efficacy of fibrinolysis and outcome. Non-
nvasive assessment of the efficacy of coronary fibrinolysis
as evaluated by a combination of clinical assessment, serial
lectrocardiograms and creatine kinase (CK) time-activity
urves. A 12-lead electrocardiogram was registered at 0, 30,
0, 90, 120, 180, 240, and 300 min after fibrinolysis
nitiation. Blood samples for CK determination were drawn
t 0, 3, 6, 9, 12, 15, and 21 h after fibrinolysis initiation. A
esolution of ST-segment elevation more than 50% at 90
in and an early peak of CK (12 h) were considered as
eperfusion criteria (16). All electrocardiograms were re-
iewed by two investigators who had no knowledge of the
enetic determinations. When electrocardiograms were
onsidered not interpretable (four patients) the early peak of
K was considered as the unique reperfusion criteria. The
fficacy of fibrinolysis and the clinical outcome were also
e-evaluated at 24 h (death, reinfarction, or necessity of
rgent PCI).
etermination of FXIII Val34Leu genotype. Total
enomic deoxyribonucleic acid was obtained from the white
lood cell following the instruction of the Wizard genomic
eoxyribonucleic acid purification system (Promega Inno-
enetics, Madrid, Spain). Genomic polymerase chain reac-
ion of the FXIII-A chain exon 2 gene was performed with
utated primers, essentially as indicated elsewhere (17).
he FXIII genotype was established after restriction of the
olymerase chain reaction product with Bsa HI (17).
tatistical analysis. Results are expressed as mean value 
tandard deviation for continuous variables and as percent-
ges for categorical variables. Univariate statistical analysis
as performed by the chi-square test. The strength of the
ssociation of the polymorphism with the occurrence of end
oints (reperfusion or clinical outcome at 24 h) was esti-
ated by calculation of the odds ratio (OR) and the
ornfield method for the calculation of 95% confidence
ntervals (CIs). Multivariate analysis was performed using
ogistic regression, Enter method (adjusting by gender, age,
al Infarction Patients
iterranean
aucasian
British
Caucasian
British
Indo-Asian
123 109 61
.5  12.2 63.8  11.0 59.0 14.2
4 (84.6) 70 (73.4) 47 (77.0)
3 (59.3) 52 (47.7) 19 (31.1)
0 (48.8) 52 (47.7) 28 (45.9)
1 (25.2) 18 (16.5) 25 (41.0)
3 (43.1) 56 (51.4) 36 (59.0)
0 (65.0) 61 (56.0) 43 (70.5)
8 (30.9) 42 (38.5) 16 (26.2)
5 (4.1) 6 (5.5) 2 (3.3)
0.805 0.752 0.836
0.195 0.248 0.164
lic on repeated observations, or if no blood pressure values were available when the
oker was considered when the subject smokes more than 10 cigarettes per day.cardi
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January 4, 2005:25–9 FXIII Polymorphism and Fibrinolytic Therapyime delay, cardiovascular risk factors, ethnicity, and fi-
rinolytic agent). Statistical analysis was performed using
he SPSS statistical package for Windows 10.0 software
SPSS Inc., Chicago, Illinois) and Epi-Info software (Cen-
ers for Disease Control and Prevention, Atlanta, Georgia).
ifferences with a two-tailed p value0.05 were considered
ignificant.
ESULTS
linical characteristics and genetic frequencies are summa-
ized in Table 1. We did not detect any age or gender
ifferences, and the distribution of genotypes was not
ignificantly different from Hardy-Weinberg proportions
data not shown). The prevalence of the FXIII Val34Leu
olymorphism in the different ethnic groups (Val/Leu 
eu/Leu: Mediterranean Caucasians 35.0%; British Cauca-
ians 44.0%; and Indo-Asians 29.5%) was broadly similar to
hat previously described (11–14,17).
ibrinolytic therapy. In the univariate analysis, only the
XIII Val34Leu polymorphism was statistically associated
ith the efficacy of fibrinolytic therapy (Table 2) and clinical
Table 2. Risk Factors for Non-Reperfusion Fo
Myocardial Infarction
Crude OR (95%
Age 1.00 (0.98–1.02)
Male gender 1.09 (0.60–1.99)
Smoker 0.72 (0.44–1.19)
Diabetes mellitus 1.38 (0.80–2.40)
Hypercholesterolemia 1.12 (0.69–1.83)
Hypertension 1.18 (0.72–1.92)
Fibrinolytic drug 0.92 (0.70–1.20)
Ethnicity 1.05 (0.88–1.26)
Time delay
Q1–Q2 1.23 (0.60–2.53)
Q1–Q3 1.28 (0.63–2.60)
Q1–Q4 1.37 (0.67–2.83)
FXIII Leu34 allele carrier 1.65 (1.00–2.73)
Univariate analysis performed by chi-square test. Multivariate
analyzed by quartile intervals, all compared with Q1. Time delay
CI  confidence interval; FXIII  factor XIII; Leu  le
Table 3. Risk Factors for Death, Reinfarction,
Crude OR (95%
Age 0.99 (0.96–1.01)
Male gender 1.15 (0.65–2.04)
Smoker 0.71 (0.44–1.13)
Diabetes mellitus 1.34 (0.79–2.29)
Hypercholesterolemia 1.32 (0.83–2.12)
Hypertension 1.00 (0.63–1.60)
Fibrinolytic drug 0.98 (0.76–1.27)
Ethnicity 1.09 (0.92–1.30)
Time delay
Q1–Q2 1.00 (0.49–2.02)
Q1–Q3 1.24 (0.62–2.45)
Q1–Q4 1.63 (0.81–3.35)
FXIII Leu34 allele carrier 1.75 (1.08–2.84)
Univariate analysis performed by chi-square test. Multivariate
analyzed by quartile intervals, all compared with Q1. Time delay: Q1:
Abbreviations as in Table 2.utcome at 24 h (Table 3). The percentage of efficacy of
brinolytic drugs was 60.6% in Leu34 allele carriers versus
1.7% in patients with the Val/Val genotype (p  0.049; OR
.65, 95% CI 1.00 to 2.73). Moreover, 52.3% of Leu34 allele
arriers were free of end points at 24 h, compared to 65.8% of
atients with the Val/Val genotype (p 0.023; OR 1.75, 95%
I 1.08 to 2.84). There were no statistically significant differ-
nces in the success rate of fibrinolytic therapy between clinical
haracteristics, age, type of fibrinolytic drugs, blood pressure, or
ime delay (Tables 2 and 3). Importantly, ethnicity did not
ave a significant influence on fibrinolytic efficacy or the 24-h
utcome (Tables 2 and 3).
In the multivariate analysis (logistic regression), fibrinolysis
n Leu34 allele patients was significantly less efficient than that
chieved among patients carrying the Val/Val genotype
p  0.021, OR 1.90, 95% CI 1.10 to 3.28) (Table 2).
e-evaluation at 24 h revealed that the FXIII Val34Leu
olymorphism was the only factor displaying a significant role
p  0.006, OR 2.14, 95% CI 1.25 to 3.68) (Table 3).
Smoking habit did not significantly influence fibrinolytic
herapy efficacy on a crude analysis (Table 3), but after
ng Fibrinolytic Therapy for Acute
p Value Adjusted OR (95% CI); p Value
0.914 0.98 (0.96–1.01); p  0.240
0.789 1.01 (0.52–1.98); p  0.968
0.210 0.63 (0.35–1.13); p  0.120
0.251 1.31 (0.71–2.44); p  0.386
0.648 1.20 (0.70–2.06); p  0.497
0.515 1.12 (0.63–1.97); p  0.705
0.523 0.83 (0.58–1.20); p  0.326
0.607 1.11 (0.87–1.41); p  0.419
0.580 1.30 (0.61–2.79); p  0.493
0.502 1.46 (0.69–3.07); p  0.318
0.392 1.34 (0.62–2.87); p  0.454
0.049 1.90 (1.10–3.28); p  0.021
s performed by logistic regression, Enter method. Time delay
90 min; Q2: 91–139 min; Q3: 140–240 min; Q4:240 min.
OR  odds ratio; Q  quartile.
rgent PCI at 24 h
p Value Adjusted OR (95% CI); p Value
0.573 0.98 (0.96–1.00); p  0.079
0.626 1.11 (0.58–2.14); p  0.753
0.149 0.56 (0.32–1.00); p  0.049
0.277 1.45 (0.79–2.67); p  0.231
0.242 1.33 (0.78–2.25); p  0.293
0.990 0.97 (0.55–1.69); p  0.908
0.877 0.87 (0.61–1.25); p  0.452
0.321 1.16 (0.91–1.47); p  0.221
1.000 1.07 (0.51–2.25); p  0.860
0.544 1.44 (0.71–2.97); p  0.318
0.171 1.60 (0.77–3.68); p  0.208
0.023 2.14 (1.25–3.68); p  0.006
s performed by logistic regression, Enter method. Time delayllowi
CI);
; p 
; p 
; p 
; p 
; p 
; p 
; p 
; p 
; p 
; p 
; p 
; p 
analysior U
CI);
; p 
; p 
; p 
; p 
; p 
; p 
; p 
; p 
; p 
; p 
; p 
; p 
analysi
90 min; Q2: 91–139 min; Q3: 140–240 min; Q4240 min.
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FXIII Polymorphism and Fibrinolytic Therapy January 4, 2005:25–9djustment for clinical variables, this was associated with a
etter outcome at 24 h (p  0.049).
As previous observations have described a higher rate
f reperfusion in smokers (18–20), we also analyzed the
ossible synergistic interaction between FXIII Val34Leu
olymorphism and smoking habit. In a multivariate
nalysis, the simultaneous combination of Leu34 allele
nd nonsmoking status increased the risk to non-
eperfusion (p  0.003, OR 3.77, 95% CI 1.55 to 9.16)
nd a worse outcome at 24 h (p  0.001, OR 4.55, 95%
I 1.89 to 10.97) (Figs. 1A and 1B).
ISCUSSION
onsistent studies have demonstrated that primary PCI
ay be the preferred reperfusion strategy in acute MI, with
eduction in death, reinfarction, and stroke compared to
brinolytic therapy (21). Unfortunately, several features
imit the availability of PCI in a significant proportion of
atients (22). Hence, renewed interest has arisen about
nitiatives that could improve the fibrinolytic efficacy, in-
luding pre-hospital fibrinolysis programs, new therapeutic
igure 1. (A) Influence in fibrinolytic efficacy of the interaction between
moking habit and factor XIII Val34Leu polymorphism (logistic regres-
ion, Enter method, after adjusted by age, gender, cardiovascular risk
actors, time delay, and fibrinolytic drug). (B) Influence in outcome at 24 h
ollowing fibrinolytic efficacy of the interaction between smoking habit and
actor XIII Val34Leu polymorphism (logistic regression, Enter method,
fter adjusted by age, gender, cardiovascular risk factors, time delay, and
brinolytic drug). Leu  leucine; OR  odds ratio; val  valine.gents (tenecteplase), or new pharmacological reperfusion btrategies (e.g., half-dose fibrinolytic agent plus glycoprotein
Ib/IIIa receptor blockade) (23).
Pharmacogenetics has emerged as a new field in medicine
hat tries to identify gene variants able to explain the
eterogeneity in patient response to a drug (24). Polymor-
hisms affecting disposition, metabolism, transporters, or
argets of the drug could modify the individual response to
ne therapy, and its side effects (25). The present study
xplores the hypothesis that there is a genetic influence on
brinolytic therapy efficacy, by analyzing the role of a
ommon polymorphism that affects the target of fibrinolytic
rugs. Only one recent study has analyzed the role of the
-1562T polymorphism affecting the promoter region of
he matrix metalloproteinase-9 gene in the haemorrhagic
ransformation of stroke after fibrinolytic therapy in 61
atients, finding no significant effect (26). Therefore, to the
est of our knowledge, our study is the first prospective one
upporting a significant pharmacogenetic effect of one
olymorphism in fibrinolytic therapy.
The main finding of the present prospective study in two
ifferent European populations (including three ethnic
roups—Mediterranean white Caucasians, British white
aucasians, and British Indo-Asians) is that FXIII
al34Leu polymorphism was independently associated with
ess efficient fibrinolysis for acute MI. Accordingly, Leu34
llele carriers had a two-fold risk to not achieve optimal
eperfusion, as well as a worse outcome at 24 h. These
esults are similar to those observed in a previous small and
etrospective cohort of survivors of premature MI (15). All
ur results support the observation that the FXIII Val34Leu
olymorphism could modify the therapeutic effect of fi-
rinolytic drugs, and this presumption is also supported by
he biochemical and haemostatic effect of the FXIII
al34Leu polymorphism: the Leu34 allele associates with
ncreased FXIII activation by thrombin, affecting the struc-
ure and resistance of the cross-linked fibrin clot (10).
Additionally, our study suggests a synergistic effect be-
ween FXIII Val34Leu polymorphisms and smoking. The
imultaneous combination of one Leu34 allele and non-
mokers significantly increases the risk of poorer efficacy of
brinolysis and a worse 24-h outcome. Smoking habit has
een demonstrated to modify the effect of fibrinolytic therapy,
ith the highest reperfusion rate in smokers (18–20). Different
ypotheses in this setting relate to a greater contribution of
hrombus to the initiation of coronary occlusion (18) and
mpaired acute endogenous fibrinolytic capacity in smokers
27). Both mechanisms could enhance the influence of the
XIII polymorphism. These results support that a combina-
ion of genetic and environmental factors could explain the
road heterogeneity of fibrinolytic therapy efficacy.
Interestingly, the influence of the FXIII Leu34 allele on
brinolytic therapy was similar in the three main popula-
ions analyzed in our study, even after adjusting for several
ossible confounders. This is relevant because the pro-
hrombotic role of this polymorphism has been suggested to
e different in the three populations (11–14,17).
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January 4, 2005:25–9 FXIII Polymorphism and Fibrinolytic Therapytudy limitations. One possible limitation of our study
ay be the assessment of the reperfusion efficacy by classical
oninvasive criteria (16). To achieve optimal Thrombolysis
n Myocardial Infarction (TIMI) flow grade 3 has been
onsidered the goal of reperfusion (6,28), with independent
rognostic value (29). However, recent studies have dem-
nstrated renewed interest in ST-segment recovery as an
ccurate marker of myocardial reperfusion (30,31), whereas
ime-activity curves of myocyte necrosis markers have been
onsistently described as good indices of reperfusion (31–33).
In conclusion, in a prospective cohort of nonselected
onsecutive acute MI patients from three different ethnic
roups, we show clinical evidence that the FXIII Leu34
llele reduces the efficacy of fibrinolytic therapy and confers
he worst clinical outcome at 24 h. Additionally, a syner-
istic association is observed between smoking habit and
XIII polymorphism. The present findings could have
mportant influence in clinical practice. For example, the
evelopment of a rapid determination of FXIII Val34Leu
olymorphism at bedside could help determine the more
ppropriate reperfusion strategy in acute MI patients, in-
orming clinicians on the necessity of performing an urgent
CI or planning the possibility of rescue angioplasty.
eprint requests and correspondence: Prof. Vicente Vicente,
entro Regional de Hemodonación, Ronda de Garay s/n 30003,
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